3 Most Promising Cancer Drugs in Late-Stage Development
Progress marches on in the fight against cancer. While more biosimilars are becoming available for top cancer drugs of the past, biopharmaceutical companies are developing newer and more powerful treatments.
Market research firm EvaluatePharma evaluated all of the experimental cancer drugs in late-stage development. The firm ranked these drugs by projected worldwide sales five years from now -- assuming the drugs win regulatory approval. Eli Lilly (NYSE: LLY), Incyte (NASDAQ: INCY), and Johnson & Johnson (NYSE: JNJ) each landed a top spot in that ranking for their pipeline candidates. Here are the three most promising cancer drugs in late-stage development.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
€137.48
-0.230%
The stock is one of the favorites of our community with 56 Buy predictions and 2 Sell predictions.
With a target price of 163 € there is a slightly positive potential of 18.56% for Johnson & Johnson compared to the current price of 137.48 €.
